Vacunacionadultos

University of Toronto professors honoured with top research awards from Natural Sciences and Engineering Research Council of Canada

University of Toronto professors are being recognized with the John C. Polanyi Award, the Brockhouse Canada Prize, two E.W.R. Steacie Memorial Fellowships, and the Gerhard Herzberg Canada Gold Medal for Science and Engineering – top research prizes from the Natural Sciences and Engineering Research Council of Canada (NSERC).

“The University of Toronto congratulates these extraordinary researchers on this important recognition of their path-breaking work,” said University Professor Ted Sargent, U of T’s vice-president of research and innovation and strategic initiatives. “Their leadership and dedication is having a significant impact on the lives of people across Canada and around the world.”

The prizes were announced Nov. 10 by Governor General Julie Payette, Minister of Innovation, Science and Industry Navdeep Bains, and Professor Alejandro Adem, president of NSERC.

“These researchers exemplify Canada’s culture of curiosity and innovation, and are making the breakthroughs that have the power to improve the lives

Read More

Information Sciences Students at The University of South Carolina Build A Digital Identity Blockchain Providing Validated Identities for All

COLUMBIA, S.C., Nov. 10, 2020 (SEND2PRESS NEWSWIRE) — The ValidIDe Project announces today the launch of its Indiegogo Fundraiser Campaign ( https://www.indiegogo.com/projects/the-validide-project ) providing Perks to contributors in support of developing the ValidIDe digital identity blockchain network.

Whether online or in the real world, there’s no simple way to verify who you are or who you claim to be other than your driver’s license. By having to give that document out, sometimes you are revealing all your personal identity information (PII) when it isn’t necessary.

Imagine a solution where restaurants, bars, banks, governments, employers, hospitals, and others all have an accurate way to verify your identity and you don’t have to worry about who is looking over your shoulder. Your personal information that isn’t needed is safe and secure and the information that you do need is at your fingertips.

Students in the School of Information Sciences at the University

Read More

These are science’s Top 10 erroneous results

To err is human, which is really not a very good excuse.

And to err as a scientist is worse, of course, because depending on science is supposed to be the best way for people to make sure they’re right. But since scientists are human (most of them, anyway), even science is never free from error. In fact, mistakes are fairly common in science, and most scientists tell you they wouldn’t have it any other way. That’s because making mistakes is often the best path to progress. An erroneous experiment may inspire further experiments that not only correct the original error, but also identify new previously unsuspected truths.

Still, sometimes science’s errors can be rather embarrassing. Recently much hype accompanied a scientific report about the possibility of life on Venus. But instant replay review has now raised some serious concerns about that report’s conclusion. Evidence for the gas phosphine, a

Read More

Gilead Sciences or Abbott Laboratories?

The coronavirus pandemic in the U.S. is now in its third wave. For stock investors, it’s important to have at least one stock in your portfolio that can perform well amid the pandemic. Whether that’s a business that does testing, is working on a vaccine, or provides a treatment option for COVID-19, a good coronavirus stock can help generate some returns for the foreseeable future, while other investments may struggle during these challenging times. It’s also a great way to diversify your portfolio.



a woman sitting in a chair talking on a cell phone: Better Coronavirus Stock: Gilead Sciences or Abbott Laboratories?


© Provided by The Motley Fool
Better Coronavirus Stock: Gilead Sciences or Abbott Laboratories?

Two options are Gilead Sciences (NASDAQ: GILD) and Abbott Laboratories (NYSE: ABT). Gilead is well-known for its drug remdesivir, which can help treat patients with COVID-19, while Abbott has been a major player in testing for the virus. Let’s take a close look at these two companies to see which one is

Read More

Retired dentistry professor helps fund University of Alberta’s new health sciences library

A large donation from a retired dentistry professor and his wife will help the University of Alberta build a new health sciences library at the Edmonton Clinic Health Academy.

Geoffrey Sperber and his wife, Robyn, donated to the school more than a year ago. Their contributions were recognized Wednesday in a private, physically distanced reception at the university.

At his request, the donation amount is not being disclosed publicly, but according to the university it is one of the largest donations ever made to the school’s library system.

The gift comes at an opportune time as the university proceeds with restructuring plans to reduce its overall expenses by $120 million over the next three years.

“It does relieve my tax bill,” Sperber told CBC News. “But the money is devoted to what I wish it to be: enlarging the student capabilities, education and research facilities of the university.”

In a

Read More

Greenwich LifeSciences, Inc. to Participate at Texas Life Sciences Forum Investor Conference

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that it was selected to present at the 2020 Texas Life Science Forum conference to be held virtually from November 10-12, 2020.

Snehal Patel, CEO of Greenwich LifeSciences, will present and will be available to participate in one-on-one meetings with members of the investor community who are registered to attend the conference. The presentation will be held between approximately 12:00-12:50 pm EST on November 10, 2020, and will highlight the Company’s GP2 program and its plans to commence a Phase III clinical trial. The presentation will be followed by a question and answer session from a 3 member panel of investors. The Company will also participate in a showcase event between approximately 4:30-5:00 pm EST on the

Read More

AbCellera and Kodiak Sciences Enter Second Antibody Discovery Collaboration for Ophthalmology Targets

AbCellera and Kodiak Sciences Inc. (Nasdaq: KOD), today announced a new partnership to generate therapeutic antibody candidates in ophthalmology. Following a previously successful collaboration, AbCellera will use its full stack, AI-powered antibody discovery technology to discover and identify a large panel of antibodies against new targets designated by Kodiak.

“Kodiak was one of AbCellera’s very first partners, and we are proud to expand our collaboration to support their innovative team in the fight against retinal diseases that cause blindness,” said Carl Hansen, Ph.D., President and CEO of AbCellera. “We are committed to making state-of-the-art antibody discovery broadly available to partners, empowering them to bring new therapies to patients quickly.”

Kodiak develops disruptive products and platforms to prevent and treat the leading causes of blindness. Kodiak’s ABC Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak’s discovery engine.

“In our

Read More

Sai Life Sciences to significantly expand biology capabilities at its integrated R&D campus

– Commences construction of new 75,000 sq. ft. facility in Hyderabad

– Augmenting India team to 170 biologists

HYDERABAD, India, Oct. 26, 2020 /PRNewswire/ — Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMO), today announced plans to significantly expand its biology capabilities at its integrated R&D campus in Hyderabad, India with a dedicated 75,000 sq. ft. facility and an augmented team of 170 biologists. The new facility will house expanded in vitro and in vivo biology services, DMPK and toxicology capabilities with the first set of labs scheduled to open in March 2021.

Upcoming Discovery Biology facility of Sai Life Sciences in Hyderabad, India
Upcoming Discovery Biology facility of Sai Life Sciences in Hyderabad, India

Making the announcement, CEO & Managing Director of Sai Life Sciences, Krishna Kanumuri said, “We aspire to deliver over 100 development candidates for our innovator partners by 2025. Our growing discovery biology team co-located with our teams

Read More

Clarkson University Names Founding Dean of the Lewis School of Health Sciences

Lenn Johns
Lenn Johns
Lenn Johns

Potsdam, NY, Oct. 19, 2020 (GLOBE NEWSWIRE) — After conducting a nationwide search, Clarkson University today announced Dr. Lennart D. Johns as founding dean of its Earl R. and Barbara D. Lewis School of Health Sciences.  

Johns will lead the Lewis School through a pivotal period that will strengthen and expand a growing portfolio of programs in the health sciences that assure the highest quality of education for students and advance careers, research and innovation with an emphasis on meeting rural and distance-challenged healthcare needs.   

Clarkson Provost Robyn Hannigan is looking forward to collaborating with Johns and the faculty to create a new identity for the health sciences across the University and externally through community impact.  “With Johns’ experiences and leadership, Clarkson is well poised for national prominence in rural healthcare. Johns understands the reality of the need for more quality rural healthcare options. He passionately

Read More

UW Genome Sciences

Upcoming Events


Tuesday, May 19

Dissertation Defense: Nick Hasle
(Fowler Lab, Ph.D. in Genome Sciences)

“Using visual phenotypes to dissect sequence-function relationships and complex drug responses”

1:30 | flier | defense will be held remotely

Thursday, May 21

Dissertation Defense: Sarah Hilton
(Bloom Lab, Ph.D. in Genome Sciences)

“Modeling the effects of site-specific amino-acid preferences on protein evolution”

2:00 | defense will be held remotely

 

For a complete listing of GS events, please see the events calendar.





New Faculty


Genome Sciences is delighted that Dr. Alison Feder has accepted our offer to be an assistant professor and will join the department in 2021. Dr. Feder is currently a Miller Fellow at the University of California, Berkeley. She is a mathematical biologist who studies evolutionary forces that drive rapid adaptation, such as that seen in

Read More